ArticleCritical care (London, England)2014
Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: a cross-sectional study.
Article in Critical care (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- A genome- and phenome-wide association study of plasma procalcitonin concentrations in individuals of European ancestry.EBioMedicine · 2026Pooled it
- Diagnostic value of procalcitonin for bacterial infections in patients undergoing hemodialysis: a systematic review and meta-analysis.Renal failure · 2022Pooled it
- Predictive value of miR-151a-3p for the onset of sepsis-induced acute kidney injury and its functional role during disease development.BMC immunology · 2026Article
- Sepsis biomarkers: recent advances and future perspectives.Frontiers in immunology · 2026Review
- First Signs at Admission: Prognostic Value of Initial Proinflammatory Markers for Sepsis and Mortality in ICU Patients.Pathogens (Basel, Switzerland) · 2025Article
- The potential role of leukocytes cell population data (CPD) for diagnosing sepsis in adult patients admitted to the intensive care unit.Clinical chemistry and laboratory medicine · 2025Observational
- Changes of Procalcitonin Kinetics According to Renal Clearance in Critically Ill Patients with Primary Gram-Negative Bloodstream Infections.Infectious diseases & clinical microbiology · 2024Article
- A biomarker panel of C-reactive protein, procalcitonin and serum amyloid A is a predictor of sepsis in severe trauma patients.Scientific reports · 2024Observational
- Prognostic Value of Macrophage Inflammatory Protein-3alpha (MIP3-Alpha) and Severity Scores in Elderly Patients with Sepsis.Journal of inflammation research · 2024Article
- Kaempferol improves acute kidney injury via inhibition of macrophage infiltration in septic mice.Bioscience reports · 2023Article
- The Potential Role of Neutrophil-Reactive Intensity (NEUT-RI) in the Diagnosis of Sepsis in Critically Ill Patients: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2023Article
- Interest of Procalcitonin in ANCA Vasculitides for Differentiation between Flare and Infections.International journal of molecular sciences · 2023Article
- Systemic inflammation as a biomarker of seizure propensity and a target for treatment to reduce seizure propensity.Epilepsia open · 2023Review
- Diagnostic and Prognostic Roles of C-Reactive Protein, Procalcitonin, and Presepsin in Acute Kidney Injury Patients Initiating Continuous Renal Replacement Therapy.Diagnostics (Basel, Switzerland) · 2023Article
- Identification of potential diagnostic and prognostic biomarkers for sepsis based on machine learning.Computational and structural biotechnology journal · 2023Article
- The Sustained and Marked Elevation of Serum Procalcitonin in a Hemodialysis Patient with Tuberculous Lymphadenitis, but Without the Evidence of Sepsis: A Case Report.Infection and drug resistance · 2022Article
- Host Diagnostic Biomarkers of Infection in the ICU: Where Are We and Where Are We Going?Current infectious disease reports · 2021Review
- Article
- Determination of the Optimal Procalcitonin Threshold for Infection in Patients With Impaired Renal Function at a Community Hospital.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2020Article
- Biomarkers of sepsis: time for a reappraisal.Critical care (London, England) · 2020Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough the clinical application of procalcitonin (PCT) as an infection marker in patients with impaired renal function (estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m(2)) has been increasing recently, it is unclear whether PCT is more accurate than C-reactive protein (CRP). We investigated the clinical value of CRP and PCT based on renal function.
methodsFrom November 2008 to July 2011, a total of 493 patients who simultaneously underwent CRP and PCT tests were enrolled. The area under the receiver operating characteristic (ROC) curve and characteristics of both markers were analyzed according to infection severity and renal function.
resultsIn patients with impaired renal function, the area under the ROC curve was 0.876 for CRP and 0.876 for PCT. In patients with infection, CRP levels differed depending on whether the infection was localized, septic, or severely septic, whereas PCT levels were higher in patients with severe sepsis or septic shock. In patients without infection, CRP did not correlate with eGFR, while PCT was negatively correlated with eGFR.
conclusionThis study demonstrates that CRP is accurate for predicting infection in patients with impaired renal function. The study suggests that in spite of its higher cost, PCT is not superior to CRP as an infection marker in terms of diagnostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.